share_log

CannaPharmaRx Receives Cultivation License From Health Canada and Projects 2023 Revenue Over $30 Million

CannaPharmaRx Receives Cultivation License From Health Canada and Projects 2023 Revenue Over $30 Million

坎納帕瑪律公司獲得加拿大衛生部和項目 2023 年收入超過 3000 萬美元的種植許可
GlobeNewswire ·  2022/12/21 10:50

CALGARY, AB, Dec. 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --  CannaPharmaRx, Inc. (OTC PINK:CPMD)(the "Company"), an emerging leader in development and operation of ultramodern, highly efficient cannabis grow facilities, announced today Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada.

卡爾加裡,AB,2022年12月21日(Global Newswire)--通過NewMediaWire網站。 CannapharmaRx公司(場外交易代碼:CPMD)(“公司”)是開發和運營超現代、高效大麻種植設施的新興領先者,該公司今天宣佈,加拿大衛生部已向該公司頒發了種植許可證。因此,CannapharmaRx現在可以合法地種植大麻,並將其作物出售給加拿大各地的其他有執照的生產商和有執照的批發商。

Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. 

加拿大衛生部是加拿大聯邦政府負責國家衛生政策的部門。它批准和監督所有大麻產品的生產,並為所有參與大麻行業的公司頒發許可證。加拿大衛生部要求所有大麻產品必須符合聯盟監管要求,才能在加拿大銷售。新的許可證命名為LIC-3JCQW6DIU0,是生產前的最後幾個主要步驟之一。這種標準種植許可證是持有許可證的大麻種植者希望在大規模設施中建造和種植以擴大企業的先決條件。

Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during Q1 2023 resulting in estimated 12 month revenues  of $30 million.

種植許可證的批准使該公司能夠合理地預計完成最初的第一次收穫,並在2023年第一季度開始銷售該作物,從而估計12個月的收入為3,000萬美元。

"The Company's facility in Cremona is now in final preparations  to open shortly," Nick Colvin, CPMD CEO stated. "Armed with our new cultivation license, the rights to several genetic strains and a very lucrative offtake agreement, we are primed to enter the cannabis market.  We remain on track to complete our first harvest and commence distribution during the next few months. We expect these factors to quickly yield rapid revenue expansion over the next twelve months." 

CPMD首席執行官尼克·科爾文表示:“公司在克雷莫納的工廠目前處於最後準備階段,不久將開業。”有了我們的新種植許可證、幾個基因菌株的權利和一份非常有利可圖的承購協定,我們已經準備好進入大麻市場。我們仍在按部就班地完成第一次收穫,並在未來幾個月開始分銷。我們預計這些因素將在未來12個月內迅速產生收入增長。

About CannaPharmaRx, Inc.
CannaPharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannaPharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannaPharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

關於CannapharmaRx公司
CannapharmaRx專注於在加拿大收購和開發最先進的大麻種植設施。CPMD正在與其他公司就潛在的收購進行談判。CannapharmaRx的商業戰略是通過開發、收購和增強現有設施,成為高質量和低成本大麻生產的領先者。CannapharmaRx致力於利用最新的熱電聯產技術運營高質量的設施,以確保成為低成本的大麻生產商。

Safe Harbor Statement
Cautionary Note Regarding Forward-Looking Information or Statements
This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannaPharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannaPharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

安全港聲明
有關前瞻性資訊或陳述的注意事項
本新聞稿包含前瞻性資訊或陳述。所有屬於或不屬於歷史事實的陳述,包括但不限於關於未來估計、計劃、計劃、預測、預測、目標、假設、預期或對未來表現的信念的陳述,都是前瞻性資訊或陳述。前瞻性資訊或陳述可以通過使用“計劃”、“預期”、“不預期”、“預計”、“估計”、“打算”、“預期”、“不預期”或“相信”等詞語或短語的變體,或某些行動、事件或結果“可能”、“可能”、“將”、“可能”或“將”採取、發生或實現的詞語和短語或陳述來識別。關於本文中包含的前瞻性資訊和陳述,CannapharmaRx管理層做出了許多假設,其中包括對一般商業和經濟狀況的假設。此類前瞻性陳述基於假設,涉及已知和未知的風險、不確定性和其他因素,這些風險、不確定性和其他因素可能導致實際結果、事件或發展與此類前瞻性資訊或陳述明示或暗示的任何未來結果、事件或發展大相徑庭。告誡讀者不要過度依賴此類前瞻性資訊或陳述。不能保證前瞻性陳述將被證明是準確的,因為實際結果和未來事件可能與前瞻性資訊或陳述中預期的大不相同。CannapharmaRx不承擔更新任何前瞻性資訊或陳述的義務,即使新資訊因未來事件、新資訊或法律要求以外的任何其他原因而可用。


Contact Information:
Brokers and Analysts:
Chesapeake Group
(410) 825-3930


聯繫方式:
經紀人和分析師:
切薩皮克集團
(410) 825-3930


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論